Abstracts tagged "Cardiovascular disease"

Abstract Number: 2456 • 2019 ACR/ARP Annual Meeting
Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Vinod Chandran ², Dafna Gladman ³ and Lihi Eder ⁴, ¹University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: Valuable information on cardiovascular disease outcomes can be obtained from large cohort studies. Such studies often rely on self-reported events, which are best validated…
Abstract Number: 346 • 2019 ACR/ARP Annual Meeting
Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Chio Yokose¹, Na Lu ², Michael Chen-Xu ³, Natalie McCormick ⁴, Michael Pillinger ⁵, Yuqing Zhang ¹ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Capital and Coast District Health Board, Wellington, New Zealand, ⁴Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁵New York University School of Medicine, New York
Background/Purpose: Gout is a very prevalent condition associated with many metabolic and cardiorenal comorbidities. A few studies have investigated the comorbidity subtypes of gout patients…
Abstract Number: 1851 • 2019 ACR/ARP Annual Meeting
The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus
S Sam Lim¹, Gaobin Bao ¹, Charles Helmick ², Charmayne Dunlop-Thomas ³ and Cristina Drenkard ¹, ¹Emory University, Atlanta, GA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ³Emory University, Atlanta, Georgia
Background/Purpose: African Americans (AA) are more likely to experience psychosocial and environmental stressors and develop SLE than whites. Increasing frequency of racial discrimination is associated…
Abstract Number: 2515 • 2019 ACR/ARP Annual Meeting
Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis
Natalia Palmou-Fontana¹, DAVID MARTINEZ-LOPEZ ², ALFONSO CORRALES ³, Fernanda Genre ⁴, SUSANA ARMESTO ⁵, MARCOS GONZALEZ ⁶, PATRICIA VICENTE-GOMEZ ⁷, JAVIER GARCIA-FERNANDEZ ⁶, VIRGINIA PORTILLA- GONZALEZ ⁵, MONICA PEREZ-ANDRES ⁵, Mónica Calderón-Goercke ⁸, DIANA PRIETO- PENA ¹, Ricardo Blanco ⁹, JOSE LUIS HERNANDEZ ¹⁰, MIGUEL ANGEL GONZALEZ-GAY ¹¹ and Iván Ferraz-Amaro ¹², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³Universitary Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁵UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, ⁶UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁰UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, ¹¹UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, ¹²Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain
Background/Purpose: Objectives. The addition of carotid ultrasound CU into composite cardiovascular risk (CVR) scores has been found useful in the identification of high CVR in…
Abstract Number: 373 • 2019 ACR/ARP Annual Meeting
Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis
Patrice Cacoub¹, Catherine Chapelon Abric ², Matthieu Resche-Rigon ³, David Saadoun ², Anne Desbois ² and Lucie Biard ³, ¹AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²GHPS, Paris, France, ³Hôpital Saint Louis, Paris, France
Background/Purpose: To identify prognostic factors and to assess the effects of immunosuppressive drugs on relapse risk in patients presenting with cardiac sarcoidosis (CS).Methods: From a…
Abstract Number: 1895 • 2019 ACR/ARP Annual Meeting
Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) may decrease cardiovascular events (CVE) in Rheumatoid arthritis (RA). We here evaluated whether bDMARDs reduce long-term CVE risk in…
Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Aladdin Mohammad¹, Pavlos Stamatis ¹ and Aleksandra Turkiewicz ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…
Abstract Number: 615 • 2019 ACR/ARP Annual Meeting
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Paras Karmacharya¹, Ravi Shahukhal ², Cynthia Crowson ³, M.Hassan Murad ⁴, Pragya shrestha ⁵, Delamo Bekele ⁶, Kerry Wright ⁴, John Davis ⁴ and Maureen Dubreuil ⁷, ¹Reading Hospital, Mayo Clinic, Rochester, ²Lakes Regional General Hospital, Laconia, NH, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic. Rochester, MN, Rochester, MN, ⁶Mayo Clinic Rochester, Rochester, MN, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: Most studies show a significantly higher risk of myocardial infarction [MI] (odds ratio [OR] = 1.60) and stroke (OR = 1.50) in ankylosing spondylitis (AS)…
Abstract Number: 2013 • 2019 ACR/ARP Annual Meeting
Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux
Kevin Real¹, Michael Duryee ¹, Patrick Opperman ¹, Evan Ryan ¹, Logan Duryee ¹, James O'Dell ², Ted Mikuls ², Daniel Anderson ¹ and Geoffrey Thiele ², ¹University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are approximately two-fold more likely to develop cardiovascular disease (CVD). Prior reports have suggested that “dysfunctional” HDL may explain…
Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Daniel Li¹, Candace Feldman ¹, Hongshu Guan ¹, Brendan Everett ², Seoyoung C. Kim ³ and Karen Costenbader ², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…
Abstract Number: 622 • 2019 ACR/ARP Annual Meeting
Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study
Jean Liew¹, John Reveille ², Henna Sawhney ³, Maria Castillo ³, Benjamin Naovarat ⁴, Susan Heckbert ¹ and Lianne Gensler ⁵, ¹University of Washington, Seattle, WA, ²University of Texas McGovern Medical School, Houston, ³University of California in San Francisco, San Francisco, CA, ⁴University of Texas-McGovern Medical School, Houston, TX, ⁵University San Francisco California, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in axial spondyloarthritis (axSpA). The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend high intensity statin…
Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting
Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Juliana Imgenberg-Kreuz¹, Christopher Sjöwall ², Martina Frodlund ², Iva Gunnarsson ³, Elisabet Svenungsson ⁴ and Dag Leonard ¹, ¹Department of Medical Sciences, Section of Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…
Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Joyce Chang¹, Taylor Goldberg ¹, Sarah McGuire ¹, Lindsay Waqar ¹, Kevin Meyers ¹, Laura Mercer-Rosa ¹, Pamela F. Weiss ¹ and Andrea Knight ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…
Abstract Number: 805 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Shivani Garg¹, Christie Bartels ¹, Cristina Drenkard ², Gaobin Bao ² and S Sam Lim ², ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Emory University, Atlanta, GA
Background/Purpose: SLE is an independent risk factor for premature cardiovascular disease (CVD) and afflicts African Americans (AA’s) 3 times more than whites. Two predominantly white…
Abstract Number: 2059 • 2019 ACR/ARP Annual Meeting
Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases
Dionicio Galarza-Delgado ¹, Jose Azpiri-Lopez ¹, Iris Colunga-Pedraza ¹, Carolina Marlene Martinez-Flores¹, Marielva Castro-Gonzalez ¹, Ileana Cecilia Reynosa-Silva ¹, Karla Paola Cuellar-Calderon ¹ and Raymundo Vera-Pineda ², ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Subjects with rheumatic diseases have an increased risk of cardiovascular (CV) morbimortality. Hypertension (HTN) is a key modifiable risk factor for CV events. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].